Intra-Cellular Therapies (ITCI) Price & Analysis

Compare

918 Followers

ITCI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$64.09 - $131.98

Previous CloseN/A

Volume92.41K

Average Volume (3M)N/A

Market Cap

$14.05B

Enterprise ValueN/A

Total Cash (Recent Filing)$1.00B

Total Debt (Recent Filing)$16.98M

Price to Earnings (P/E)―

Beta0.70

Next Earnings

May 13, 2025

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.72

Shares Outstanding55,261,000

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio-11.31

Price to Book (P/B)11.84

Price to Sales (P/S)20.56

P/FCF Ratio-191.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$130.83

Price Target Upside-0.79% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering13

Intra-Cellular Therapies News

PremiumPre-Earnings

Is ITCI a Buy, Before Earnings?

3M ago

ITCI

PremiumCompany Announcements

Intra-Cellular Therapies Completes Merger with Johnson & Johnson

4M ago

ITCI

PremiumCompany Announcements

Intra-Cellular Therapies Reports Strong 2024 Growth

5M ago

ITCI

PremiumThe Fly

Alibaba upgraded, Rivian downgraded: Wall Street’s top analyst calls

5M ago

BYD

CAG

PremiumThe Fly

Intra-Cellular downgraded to Neutral from Outperform at Mizuho

5M ago

ITCI

PremiumPre-Earnings

Is ITCI a Buy, Before Earnings?

5M ago

ITCI

PremiumRatings

Hold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition Prospects

5M ago

ITCI

PremiumThe Fly

Intra-Cellular reports Q4 EPS (16c), consensus (11c)

5M ago

ITCI

See All ITCI News

See All News >

Bulls Say, Bears Say

Bulls Say

Financial PerformanceCaplyta revenues of $199.2M were slightly above consensus, indicating better-than-expected financial performance.

Regulatory ApprovalFDA acceptance of lumateprone's sNDA for adjunctive MDD is a key update influencing the stock positively.

Strategic AcquisitionThe acquisition makes strategic sense as it appears to fit nicely within JNJ's existing neuro franchise.

Bears Say

Pending AcquisitionDowngrading to HOLD on pending acquisition by JNJ.

Pipeline UncertaintyOther ITCI pipeline products could be meaningful, but are earlier stage, making it difficult to ascribe value to them.

Stock DowngradeAnalyst is downgrading ITCI from Buy to HOLD as the stock is not trading on fundamentals.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.37% Insiders

3.29% Mutual Funds

28.29% Other Institutional Investors

96.71% Public Companies and

Individual Investors

Detailed Ownership Overview >

ITCI FAQ

What was Intra-Cellular Therapies’s price range in the past 12 months?

Intra-Cellular Therapies lowest stock price was $64.09 and its highest was $131.98 in the past 12 months.

What is Intra-Cellular Therapies’s market cap?

Intra-Cellular Therapies’s market cap is $14.05B.

When is Intra-Cellular Therapies’s upcoming earnings report date?

Intra-Cellular Therapies’s upcoming earnings report date is May 13, 2025 which is 74 days ago.

How were Intra-Cellular Therapies’s earnings last quarter?

Currently, no data Available

Is Intra-Cellular Therapies overvalued?

According to Wall Street analysts Intra-Cellular Therapies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Intra-Cellular Therapies pay dividends?

Intra-Cellular Therapies does not currently pay dividends.

What is Intra-Cellular Therapies’s EPS estimate?

Intra-Cellular Therapies’s EPS estimate is -0.08.

How many shares outstanding does Intra-Cellular Therapies have?

Intra-Cellular Therapies has 55,261,000 shares outstanding.

What happened to Intra-Cellular Therapies’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Intra-Cellular Therapies?

Currently, no hedge funds are holding shares in ITCI

Intra-Cellular Therapies Stock Smart Score

Neutral

Fundamentals

Return on Equity

-8.58%

Trailing 12-Months

Asset Growth

87.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Intra-Cellular Therapies

Intra-Cellular Therapies (ITCI) is a biopharmaceutical company focused on the development and commercialization of innovative treatments for neuropsychiatric and neurodegenerative disorders. The company's lead product, CAPLYTA (lumateperone), is an FDA-approved atypical antipsychotic for the treatment of schizophrenia in adults. ITCI is dedicated to enhancing the lives of patients by advancing a pipeline of novel drugs that target underlying causes in mental health disorders.

ITCI Stock 12 Month Forecast

Average Price Target

$130.83

▼(-0.79%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"66":"$66","133":"$133","82.75":"$82.8","99.5":"$99.5","116.25":"$116.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$132.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$130.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":118,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$118.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[66,82.75,99.5,116.25,133],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Dec<br/>2024","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.87,131.88,131.89000000000001,131.9,131.91,131.92000000000002,131.93,131.94,131.95,131.96,131.97,131.98,131.99,{"y":132,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.87,131.79,131.71,131.63,131.55,131.47,131.39000000000001,131.31,131.23000000000002,131.15,131.07000000000002,130.99,130.91000000000003,{"y":130.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.87,130.80307692307693,129.73615384615385,128.66923076923078,127.60230769230769,126.53538461538461,125.46846153846154,124.40153846153846,123.33461538461539,122.26769230769231,121.20076923076923,120.13384615384615,119.06692307692308,{"y":118,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":71.49,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.27,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.73,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.24,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.99,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.28,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.65,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.54,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Similar Stocks

RDY

Dr Reddy's Laboratories

―

VTRS

Viatris

―

NBIX

Neurocrine

―

SUPN